Experimental evidence points to the importance of the
cytokine interleukin-17A (IL-17A) in the pathogenesis of several immunoinflammatory diseases including
psoriasis,
psoriatic arthritis and
rheumatoid arthritis. Although a principal effector of T helper type 17 cells,
IL-17A is produced by many other cell types including CD8(+) T cells and γδ T cells, and is found at high levels associated with mast cells and neutrophils at sites of skin and
joint disease in humans.
IL-17A up-regulates expression of numerous
inflammation-related genes in target cells such as keratinocytes and fibroblasts, leading to increased production of
chemokines,
cytokines,
antimicrobial peptides and other mediators that contribute to clinical disease features. Importantly,
IL-17A must be considered within the context of the local microenvironment, because it acts synergistically or additively with other pro-inflammatory
cytokines, including tumour
necrosis factor. Several direct
IL-17A inhibitors have shown promising activity in proof of concept and phase 2 clinical studies, thereby providing confirmation of experimental data supporting
IL-17A in disease pathogenesis, although levels of response are not predicted by pre-clinical findings.
IL-17A inhibitors produced rapid down-regulation of the
psoriasis gene signature and high clinical response rates in patients with moderate-to-severe plaque
psoriasis, consistent with an important role for
IL-17A in
psoriasis pathogenesis. Clinical response rates with
IL-17A inhibitors in
psoriatic arthritis and
rheumatoid arthritis, however, were improved to a lesser degree compared with placebo, suggesting that
IL-17A is either important in a subset of patients or plays a relatively minor role in inflammatory
joint disease. Ongoing phase 3 clinical trials should provide further information on the role of
IL-17A in these diseases.